Clinical efficacy of Liquid biopsy for acquired resistance to afatinib in EGFR positive NSCLC

Clinical efficacy of Liquid biopsy for acquired resistance to afatinib in EGFR positive NSCLC - Liquid biopsy for acquired resistance to afatinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025112

Enrollment

100

Registered

2016-12-05

Start date

2016-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR mutation positive NSCLC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.EGFR mutation positive NSCLC 2.Patients who experienced progression during treatment with afatinib 3.Possible to submit blood sample 4.Presence of informed consent

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
Frequency of T790M in patients who experienced acquired resistance to afatinib	—

Countries

Japan

Contacts

Public ContactTatsuya Yoshida, Yuko Oya, Kentaro Ito

Aichi cancer center, Matsusaka Municipal Hospital Department of Thoracic Oncology

yshima@aichi-cc.jp052-762-6111

Outcome results